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orphan drugs (ODs). This study examined the characteristics of
OD designations and approvals in the U.S. and in the EU cen-
tralized system between August 1, 2000 and December 31, 2007
and compared the characteristics of sponsors, products and indi-
cations. METHODS: Data derived from the US FDA and the
European Medicines Agency (EMEA). Chi-Square and Fishers’
exact tests, and group comparison t-tests were used in the analy-
sis. RESULTS: In the study period, the FDA listed 773 orphan
designations and 65 (8.4%) approvals, and the EMEA listed 492
designations and 37 (7.5%) approvals. Orphan designations
were granted to 472 sponsors by the FDA and to 293 sponsors by
the EMEA. The sponsors included 30 universities, public orga-
nizations and individual sponsors in the U.S. and 20 in the EU.
The average OD designations per sponsor were 1.64  1.63 in
the U.S. and 1.68  1.51 in the EU. 68.9% of sponsors in the
U.S. and 65.9% of sponsors in the EU had only 1 OD designa-
tion. The time from OD designation to approval was
1.74  1.45 years in the FDA and 2.73  1.43 years in the
EMEA (p < 0.001). 98 (14.7%) sponsors had OD designations in
both agencies. There were 102 designations in both agencies that
had the same sponsor, product and indication; and 76 designa-
tions that had the same product and indication and different
sponsor. CONCLUSIONS: US had more designations and
approvals, but the analysis excludes ODs approved by national
European agencies. OD incentives encourage R&D by small
sponsors that, otherwise, could not assume the risk and oppor-
tunity cost associated with developing such products. The imple-
mentation of the FDA/EMEA common OD application in
November 26, 2007 aims to reduce the duplication in OD devel-
opment found in this study.
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OBJECTIVES: This study aimed to identify the most important
factors affecting the total cost and the length of stay (LOS) of
neonates who were hospitalized in six neonatal intensive care
units (NICUs) in Greece. METHODS: The study sample con-
sisted of 218 neonates who entered the NICUs of six maternity,
pediatric and general hospitals, of Greece. Multivariate Regres-
sion analysis was performed in order to examine the factors
affecting the LOS and the total cost of hospitalization. Data on
mother and father educational and occupational status, type and
number of delivery, place of residence (rural or urban), age of the
mother, birth weight and the gestational age of the infants were
available. The costs used for the analysis, emerged from a
detailed cost analysis, bottom up approach, based on daily con-
sumption of each neonate for the whole period of hospitaliza-
tion, until discharge of the hospital. Bootstrap simulation was
used with 1000 iterations in order to check for the stability of the
cost analysis. RESULTS: Factors inﬂuencing the LOS (in days)
and the total cost (in Euro) were identical in both regression
models. Factors for LOS were the type of the hospital, since in
the pediatrics hospitals neonates stayed longer than in the
maternity hospitals (coefﬁcient 17.44; 95%CI 4.61 to 30.28,
p = 0.004) and the birth weight of the neonate (coefﬁcient 25.03;
95%CI: 8.304 to 41.77, p = 0.004). Factors for the total cost
were the length of stay (coefﬁcient 228.11; 95%CI: 218.53 to
237.68, p < 0.001), the type of the hospital (coefﬁcient 993.72;
95%CI 301.03 to 1686.42, p = 0.005) and birth weight of the
infant (coefﬁcient 1528.07; 95%CI 700.61 to 2355.54,
p < 0.001). CONCLUSIONS: The ﬁndings, as expected, proved
that the lower the birth weight, the more prolonged and more
costly the hospitalization. Differences in the type and organiza-
tion between hospitals need further attention.
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OBJECTIVES: Anxiety is frequently associated with major
depressive disorder (MDD). Antidepressants are approved for
MDD and some anxiety disorders. However, few data exist on
real-life utilisation and outcomes of antidepressant treatments in
patients with MDD and co-morbid anxiety. This study aims
at describing and comparing treatment patterns, health care
resource use and associated costs in these patients. METHODS:
This cohort study using the US claims database PharMetrics
included adults with a ﬁrst prescription of an antidepressant
(escitalopram, an SSRI or venlafaxine) associated with a diagno-
sis of MDD in 2003–2005, and with two diagnoses of anxiety in
the year surrounding this ﬁrst prescription. Treatment patterns,
health care resource use and related costs were assessed during
the 6-month before and after ﬁrst prescription, and compared
across treatment groups. RESULTS: Of 18,676 patients, 69%
were women, and mean age was 40. 25% of patients were
prescribed escitalopram, 64% SSRIs, and 11% venlafaxine.
Treatment patterns showed a 15% switch rate, a 16% combina-
tion rate and 23% of stops with no subsequent relapse (success-
ful treatment stop). Both switch and combination rates were
lower with escitalopram vs. SSRIs and venlafaxine (p < 0.001
and p = 0.002 respectively). Successful treatment stops were
more frequent with escitalopram vs. venlafaxine (p < 0.001).
6-month total health care costs after treatment initiation were
not signiﬁcantly different than before (US$ 4,656 vs. US$4,254),
but the structure of costs differed, with more pharmacy costs
(20% vs. 10%), and less inpatient care (36% vs. 51%) after
treatment start. Compared with baseline costs, health care costs
were decreased with escitalopram and increased with SSRIs and
venlafaxine (-US$74 vs. + US$496 and + US$916 respectively).
CONCLUSIONS: In patients with MDD and co-morbid anxiety,
antidepressant treatment was generally associated with decreased
inpatient care. Compared with SSRIs and venlafaxine, escitalo-
pram was associated with less treatment changes and with
decreased costs.
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OBJECTIVES: This study was designed to investigate the impact
of medicaid expansion on preventable hospitalization(PH) trend.
METHODS: Data from the Korea National Health Insuran-
ce(NHI) claims andmedicaid claims database, covering 48million
Korean people, was used. The new medicaid people were selected
who were enrolled ﬁrst time during the medicaid expansion
period, the year 1998–1999. The NHI enrollees were randomly
selected for control group. All were continuously enrolled from
1996 to 2001 and aged more than 17 years. Multinomial logit
regressionmodels of comparing PHversusmarker admissionwere
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